Mitgliederinformationen

Dr Marta Morales Ballús
Spanien
Team

Dr Jaume Català Mora
Spanien

Dr Elisa Carreras
Spanien

Dr Itziar Alonso
Spanien

Dr Isabel Ayet
Spanien

Dr Ester Casas
Spanien

Optometrist Ana Díaz
Spanien

Dr Jesús Díaz
Spanien

Optometrist Enric Puigventos
Spanien

Optometrist Carles Fresno
Spanien

Dr Carmen García Vicuña
Spanien

Dr Hugo Gonzalez
Spanien

Optometrist Enrique Jimenez
Spanien

Dr Ana Llorca
Spanien

Dr Antonio Federico Martinez Monstseny
Spanien

Dr Joan Prat
Spanien

Dr Gemma Romeu
Spanien

Dr Alicia Serra
Spanien

Optometrist Simone Suh
Spanien

Dr Mariona Vidal
Spanien

Optometrist Begoña Yeste
Spanien

Dr Núria Planas
Spanien
HCP-Zentrum

Kontakt
Hospital Sant Joan de Déu, Spain
Klinische Studien

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG

A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation